Peg IFNα-2a in polycythemia vera (PV).: Results of a phase 2 study by the French "PV-NORD" group.

被引：0
|
作者：
Kiladjian, Jean-Jacques
Cassinat, Bruno
Turlure, Pascal
Cambier, Nathalie
Bellucci, Sylvia
Roussel, Murielle
Grange, Marie-Jose
Grandchamp, Bernard
Rain, Jean-Didier
Chomienne, Christine
Fenaux, Pierre
机构：
[1] Univ Paris 13, Hop Avicenne, Bobigny, France
[2] Hop St Louis, Paris, France
[3] CHU, Limoges, France
[4] CHRU, Lille, France
[5] Hop Lariboisiere, Paris, France
[6] Hop Bichat, F-75877 Paris, France
[7] Hop Bichat, INSERM, U656, F-75877 Paris, France
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2679
引用
下载
收藏
页码：757A / 757A
页数：1
相关论文
共 50 条
  • [21] Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study
    Passamonti, Francesco
    Palandri, Francesca
    Saydam, Guray
    Egyed, Miklos
    Callum, Jeannie
    Devos, Timothy
    Sivgin, Serdar
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Zor, Evren
    Gilotti, Geralyn
    Zhang, Yifan
    Griesshammer, Martin
    BLOOD, 2020, 136
  • [22] VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
    Bankar, Aniket
    Pettit, Kristen
    Shatzel, Joseph
    Yacoub, Abdulraheem
    Pemmaraju, Naveen
    Gill, Harinder
    Hlusi, Antonin
    Lucchesi, Alessandro
    Alimam, Samah
    Mayer, Jiri
    Palandri, Francesca
    Sasca, Daniel
    Modelska, Katharina
    Gupta, Suneel K.
    Ajari, Ifode
    Khanna, Sarita
    Molina, Arturo
    Kuykendall, Andrew Tucker
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] PEGYLATED INTERFERON-ALFA (IFNA) 2A TREATMENT TARGETS JAK2V617F CLONES WITHOUT AFFECTING TET2 MUTANT CELLS IN POLYCYTHEMIA VERA (PV)
    Kiladjian, J. J.
    Masse, A.
    Cassinat, B.
    Mokrani, H.
    Teyssandier, I.
    Le Couedic, J. P.
    Cambier, N.
    Almire, C.
    Pronier, E.
    Casadevall, N.
    Vainchenker, W.
    Chomienne, C.
    Delhommeau, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 453 - 453
  • [24] The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
    Mascarenhas, John
    Passamonti, Francesco
    Burbury, Kate
    El-Galaly, Tarec Christoffer
    Gerds, Aaron
    Gupta, Vikas
    Higgins, Brian
    Wonde, Kathrin
    Jamois, Candice
    Kovic, Bruno
    Huw, Ling-Yuh
    Katakam, Sudhakar
    Maffioli, Margherita
    Mesa, Ruben
    Palmer, Jeanne
    Bellini, Marta
    Ross, David M.
    Vannucchi, Alessandro M.
    Yacoub, Abdulraheem
    BLOOD ADVANCES, 2022, 6 (04) : 1162 - 1174
  • [25] Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon T. S.
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Mesa, Ruben A.
    He, Shui
    Jones, Mark
    Garrett, William M.
    Li, Jingjin
    Pirron, Ulrich
    Lawniczek, Tomasz
    Vannucchi, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] RESPONSE: A randomized, open-label, phase III study of ruxolitinib in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Sandor, Victor
    Lukawy, Jacek
    Li, Jingjin
    He, Shui
    Garrett, William M.
    Malek, Kamel
    Pirron, Ulrich
    Mookerjee, Bijoyesh
    Vannucchi, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] DTIC plus carboplatin plus IFNα2a in metastatic melanoma:: Renal Cancer and Melanoma Spanish Group.
    Gonzalez-Larriba, JL
    Crespo, C
    Maurel, J
    Campos, JM
    Guillen, V
    Llanos, M
    Dorta, J
    Berrocal, A
    Garcia, AL
    Garrido, P
    Moyano, AJ
    ANNALS OF ONCOLOGY, 2000, 11 : 130 - 130
  • [28] A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter
    Levy, Richard
    Bradley, Edward C.
    Schacter, Lee
    Garrett, William M.
    Vaddi, Kris
    Contel, Nancy
    Rumi, Elisa
    Gattoni, Elisabetta
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro
    BLOOD, 2009, 114 (22) : 132 - 132
  • [29] Decrease in JAK2V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV).
    Silver, Richard T.
    Vandris, Katherine
    Goldman, Joshua J.
    Adriano, Fernando
    Wang, Y. Lynn
    Jones, Amy V.
    Christos, Paul J.
    Cross, N. C. P.
    BLOOD, 2009, 114 (22) : 757 - 758
  • [30] Histomorphological Responses after Therapy with Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
    Masarova, Lucia
    Yin, C. Cameron
    Cortes, Jorge E.
    Konopleva, Marina
    Borthakur, Gautam
    Newberry, Kate J.
    Kantarjian, Hagop M.
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
12345